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Abstract: Two series of N-(aryl)-1-(hydroxyalkyl)pyrrolidine-2-carboxamides (2a–2g and 3a–3g) and
1,4-disubstituted 1,2,3-triazoles (5a–5h and 8a–8h) were synthesized. All the compounds, containing
a lipophilic tail and a polar headgroup, were evaluated as sphingosine kinase (SphK) inhibitors
by assessing their ability to interfere with the acetylcholine (Ach) induced relaxation of aortic rings
pre-contracted with phenylephrine. Moreover, their antiproliferative activity was tested on several
cell lines expressing both SphK1 and SphK2. Compounds 5h and 8f, identified as the most efficient
antiproliferative agents, showed a different selectivity profile, with 8f being selective for SphK1.
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1. Introduction
Two isoforms of sphingosine kinase have been identified (SphK1 and SphK2) [1]. Although
they exhibit subtle differences in the substrate specificity and subcellular localization, SphK1
and SphK2 catalyze the same reaction, i.e., phosphorylation of sphingosine to produce
sphingosine-1-phosphate (S1P).
S1P is a bioactive lipid that activates a family of G protein-coupled receptors, termed S1P1–5.
SphK1 is mostly localized to the cytosol while SphK2 is mostly nuclear [2]. SphK1 and SphK2
double knockout mice exhibit a severely disturbed neurogenesis and angiogenesis, causing embryonic
lethality [3]. Nonetheless, mice knocked out for just one of the two kinases are viable, fertile,
and without any obvious abnormalities, mainly because of some compensatory activities of the two
enzymes [4,5].
The S1P pathway has a pivotal role in the control of immune cell trafficking and has been involved
in inflammatory based diseases and cancer [6–8]. Up-regulation of SphK1 has been found in a wide
array of human solid cancers and hematological malignancies [9]; the consequent elevated cellular
levels of S1P promote cell survival, proliferation [10], and angiogenesis, indicating a major implication
for SphK1 in the development and progression of cancer and chemo-resistance [11]. Nonetheless,
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high potency SphK1 inhibitors have shown effects on S1P levels but not on cell viability; moreover,
most of them have shown several off-target activities.
The potential of SphK2 as an oncology target has gained increasing interest. SphK2 can
be considered as a prognostic negative index in non-small cell lung cancer [12]. Moreover, small
interfering RNA (siRNA) knockdown studies have indicated that this isoform has a crucial role
in several cancers, including acute lymphocytic leukaemia, multiple myeloma, glioblastoma, kidney,
and breast cancer [13].
Experiments performed knocking down SphK1 and SphK2 suggest the existence
of a compensatory mechanism for the two isoforms. Thus, several research groups have focused
their attention on the development of dual inhibitors to study this phenomenon further [14,15].
On the other hand, the hunt for selective SphK1 and SphK2 inhibitors is crucial in elucidating the
specific functions of the two isoforms and has led to the description of a plethora of molecules,
most of them targeting the sphingosine-binding pocket of the enzyme [13,15,16]. The resolution
of the SphK1 crystal structure [17] has given a boost to the discovery of novel SphK inhibitors,
recently leading to the identification of potent isoform selective inhibitors. The inhibitors have
been instrumental in elucidating the roles of SphKs in the regulation of key oncogenes and their
involvement in inflammatory signaling. However, the most commonly used inhibitors failed to induce
cancer cell death [18]; moreover, important off-targets have been recently reported [19,20].
Starting from these considerations and bearing in mind the need of SphK inhibitors
to increase the possibility of having useful new therapeutic agents, we designed a first series
of N-(aryl)-1-(hydroxyalkyl)pyrrolidine-2-carboxamides (compounds 2a–2g and 3a–3g; Scheme 1).
Int. J. Mol. Sci. 2017, 18, 2332 2 of 18 
 
implication for SphK1 in the development and progression of cancer and chemo-resistance [11]. 
Nonetheless, high potency SphK1 inhibitors have shown effects on S1P levels but not on cell 
viability; moreover, most of them have shown several off-target activities. 
The potential of SphK2 as an oncology target has gained increasing interest. SphK2 can be 
considered as a prognostic negative index in non-small cell lung cancer [12]. Moreover, small 
interfering RNA (siRNA) knockdown studies have indicated that this isoform has a crucial role in 
several cancers, including acute lymphocytic leukaemia, multiple myeloma, glioblastoma, kidney, 
and breast cancer [13]. 
Experiments performed knocking down SphK1 and SphK2 suggest the existence of a 
compensatory mechanism for the two isoforms. Thus, several research groups have focused their 
attention on the development of dual inhibitors to study this phenomenon further [14,15]. On the 
other hand, the hunt for selective SphK1 and SphK2 inhibitors is crucial in elucidating the specific 
functions of the two isoforms and has led to the description of a plethora of molecules, most of them 
targeting the sphingosine-binding pocket of the enzyme [13,15,16]. The resolution of the SphK1 
crystal structure [17] has given a boost to the discovery of novel SphK inhibitors, recently leading to 
the identification of potent isoform selective inhibitors. The inhibitors have been instrumental in 
elucidating the roles of SphKs in the regulation of key oncogenes and their involvement in 
inflammatory signaling. However, the most commonly used inhibitors failed to induce cancer cell 
death [18]; moreover, important off-targets have been recently reported [19,20]. 
Starting from these considerations and bearing in mind the need of SphK inhibitors to increase 
the possibility of having useful new therapeutic agents, we designed a first series of 
N-(aryl)-1-(hydroxyalkyl)pyrrolidine-2-carboxamides (compounds 2a–2g and 3a–3g; Scheme 1). 
Cl H3C(H2C)5 H3C(H2C)6
H3C(H2C)7
n=2 2a
n=3 3a
n=2 2b
n=3 3b
n=2 2c
n=3 3c
n=2 2e
n=3 3e
n=2 2f
n=3 3f
n=2 2g
n=3 3g
n=2 2d
n=3 3d
R NH2 + N
HO
BocO
N
H
H
N
O
R N
H
N
(CH2)nOHO
R
(i)
1a-1g 2a-2g
3a-3g
(ii)
(iii)
R =
 
Scheme 1. Reagents and conditions: (i) TBTU/HOBt, dimethylformamide (DMF), 12 h; (ii) 40% 
trifluoroacetic acid (TFA) in DCM, 2 h; (iii) Br(CH2)nOH, NaI, K2CO3, DMF, 12 h. 
The newly synthesized molecules, possessing some structural elements in common with 
already known inhibitors, are characterized by the presence of a polar head linked through a 
pyrrolidine spacer to a lipophilic tail, represented by several aromatic moieties, such as 
4-chlorophenyl, 4-hexylphenyl, 4-heptylphenyl, 4-octylphenyl, α-naphthyl, 2-biphenyl, and 
4-biphenyl nuclei. All the compounds were routinely evaluated by first assessing their ability to 
interfere with the acetylcholine (Ach) induced relaxation of aortic rings pre-contracted with 
phenylephrine (PE). Roviezzo et al. have demonstrated that incubation of rat aorta rings with a 
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he newly synthesized molecules, possessing some structural elements in common with already
known inhibitors, are characterized by the presence of a olar head linked through a pyrrolidine spacer
to a lipophilic tail, represented by several aromatic moieties, such as 4-chlorophenyl, 4-hexylphenyl,
4-heptyl e yl, 4-octylphenyl, α-naphthyl, 2-biphenyl, and 4-biphenyl nuclei. All the compounds
were routinely evaluated by first assessing their ability to interfere with the acetylcholine (Ach) induced
relaxation of aortic rings pre-co tracted with phenylephrine (PE). Roviezzo et al. have demonstrated
that incubation of rat aorta rings with a SphK inhibitor produced a concentration-dependent reduction
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of Ach-induced vasorelaxation [21]. This experiment revealed that only the 4-octylphenyl derivatives
2d and 3d, at the tested concentration of 30 µM, were able to inhibit the aortic ring relaxation.
This nucleus was selected for the development of two series of triazole derivatives, the more rigid
5a–5h and the more flexible 8a–8h. The compounds were firstly evaluated on aortic rings, and then
tested for their antiproliferative ability on several cell lines expressing both SphK1 and SphK2.
2. Results and Discussion
2.1. Synthesis
The synthesis of compounds 2a–2g and 3a–3g was accomplished in three steps as outlined
in Scheme 1.
Intermediates 1a–1g were prepared by reaction of the opportune aromatic amine with Boc-Pro-OH
via 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate/1-hydroxybenzotriazole
hydrate (TBTU/HOBt) in dimethylformamide (DMF) and subsequent Boc removal with 40%
trifluoroacetic acid (TFA) in dichloromethane (DCM) for 2 h. The final compounds 2a–2g and 3a–3g
were prepared by reacting the opportune intermediate with 2-bromoethanol or 3-bromopropanol,
respectively, in the presence of a 50% excess of K2CO3 and NaI, in DMF solution. The yields, referred
to in the final step, were in the range 54–73% for the ethyl derivatives (2a–2g) and 52–84% for the
propyl derivatives (3a–3g).
Compounds 5a–5h were prepared according to the procedure depicted in Scheme 2. 4-Octylaniline
was converted to the corresponding azide 4 firstly by producing the diazonium salt by reaction with
NaNO2 in concentrated HCl and subsequently, by treatment with NaN3 in water, at 0 ◦C for 12 h.
The following Cu-catalyzed azide-alkyne cycloaddition of 4 with the opportune alkyne, performed
using Sharpless protocol [22], afforded the final desired 1,4-disubstituted 1,2,3-triazoles 5a–5h with
yields in the range 77–90%.
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2.2. Aorta Rings Assay
The effect of the potential inhibitors of sphingosine kinases (SphKs) has been evaluated
on Ach-induced vasorelaxation in isolated mouse aorta rings. Indeed, the SphK/S1P pathway
is involved in Ach-induced relaxation [21]. Aortic rings were incubated with each compound (30 min;
1–30 µM) prior to performing a cumulative dose-response to Ach. Compounds 2d (53%) and 3d (60%)
significantly inhibited Ach-induced relaxations.
These compounds were liquid and had a very low solubility in aqueous solution. For these reasons,
we designed a new series of compounds with the aim to overcome these difficulties. Considering the
inhibitory properties of the octylphenyl derivatives 2d and 3d, we synthesized two series of triazoles,
5a–5h and 8a–8h, in which the octylphenyl group is linked to a polar head using the triazole nucleus
as the linkage element. All the compounds have been tested, as described above, and most of them
displayed a significant inhibitory activity at 30 µM (Table 1).
2.3. Antiproliferative Activity
We first performed a drug screening by testing the capability of the triazole derivatives 5a–5h and
8a–8h to reduce cell density of cultured A549, H1975, and HCC827 human non-small cell lung cancer
(NSCLC) cell lines. The synthesized molecules were divided in three groups by using the dose that
reduced cell density by 50% (Table 1). For most of the compounds, the dose able to reduce cell density
by 50% was >10 µM; for compounds 5c and 5f, this dose was between 5 and 10 µM; only for 5h and 8f
was it ≤5 µM.
The four best compounds (5c, 5f, 5h, and 8f), were analyzed in a comparative manner by using
the same experimental procedure and NSCLC cell lines listed above. Compounds 5h and 8f confirmed
the results obtained in the drug screening, they were the more efficacious among the synthesized
molecules. Both the compounds were able to reduce cell density by 50% or more at the dose of 5 µM
(Figure 1) and 5h was more effective than 8f on all the tested cell lines with a 100% reduction of cell
density on HCC827 cells, when tested at 5 µM.
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We first performed a drug screening by testing the capability of the triazole derivatives 5a–5h 
and 8a–8h to reduce cell density of culture  A549, H1975, an  HCC827 human non-small cell lung 
cancer (NSCLC) cell lines. The synthesized molecules were divided in three groups y using the 
dose that reduced cell density by 50% (Table 1). For most of the compounds, the dose able to reduce 
cell density by 50% was >10 µM; for compounds 5c and 5f, this dose was between 5 and 10 µM; only 
for 5h and 8f was it ≤5 µM. 
The four best compounds (5c, 5f, 5h, and 8f), were analyzed in a comparative manner by using 
the sa e experimental procedure an  NSCLC cell lines listed above. Compounds 5h and 8f 
co firmed the res lts obtained in the drug screening, they were the more efficacious among t e 
synthesized molec les. Both the compounds were able to reduce cell density by 50% or more at the 
dose of 5 µM (Figure 1) a d 5h was more effective than 8f on all the tested cell lines with a 100% 
reduction of cell density on HCC827 cells, when tested at 5 µM. 
46 ≤5 µM
8a –C 2OH 65 >10 µM
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8c –(CH2)3OH 19.5 >10 µM
8d
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Figure 1. The compounds 5c, 5f, 5h, and 8f are able to reduce cell density of cultured NSCLC cell 
lines. Percent of cell density of A549 (A), HCC827 (B), and H1975 (C) NSCLC cells treated with 
different doses (0.5–5 µM) of the compounds 5c, 5f, 5h, and 8f for 3 days, as measured by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data represent the mean 
(±SD) of three independent experiments, each performed in triplicate. Bars show SDs. Statistical 
significance was determined by the Student t-test: p < 0.1 for compounds 5c (5 µM, A549), 5h (2.5 µM, 
all cell lines), and 8f (2.5 µM, all cell lines); p < 0.01 for compounds 5h (5 µM, all cell lines) and 8f (5 
µM, all cell lines). 
To verify the selectivity of 5h and 8f towards the two enzymatic isoforms, we performed a 
SphK activity assay. The principle of the method is to quantify, by luminescence, the remaining 
amount of adenosine triphosphate (ATP) in solution following the kinase reaction. The luminescent 
signal is inversely correlated with the kinase activity. The SphK1 competitive inhibitor PF-543 was 
used as a positive control for SphK1 and as a negative control for SphK2. As shown in Figure 2A, 
PF-543, 5h, and 8f tested at 10 µM, were able to inhibit SphK1 activity as demonstrated by the higher 
ATP levels in solution when compared to that of the control. When tested on SphK2, only compound 
5h caused an increment of ATP levels, with respect to the control, indicating that it is able to inhibit 
both the enzymes (Figure 2B). 
In order to better display these results, we converted the data to percent of inhibition, obtaining 
the graphs reported in Figure 2C,D. As displayed, PF-543 was completely ineffective on SphK2 
(Figure 2B) and selectively inhibited SphK1 (Figure 2A), even if it was less effective than expected. 
Moreover, when it was tested on A549 cells, it reduced cell density by less than 50% at 5 µM (Figure 
S1) showing an antiproliferative effect lower than that of the here reported compounds. Finally, 
compound 8f was able to selectively inhibit SphK1, while compound 5h showed a comparable 
inhibition of both the enzyme isoforms SphK1 and SphK2. This data proposes 5h as a dual inhibitor 
and might explain the higher efficacy of 5h as an antiproliferative agent. Several groups have 
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Figure 1. The compounds 5c, 5f, 5h, and 8f are able to reduce cell density of cultured NSCLC
cell lines. Percent of cell density of A549 (A), HCC827 (B), and H1975 (C) NSCLC cells treated
with different doses (0.5–5 µM) of the compounds 5c, 5f, 5h, and 8f for 3 days, as measured
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data represent the
mean (±SD) of three independent experiments, each performed in triplicate. Bars show SDs. Statistical
significance was determined by the Student t-test: p < 0.1 for compounds 5c (5 µM, A549), 5h (2.5 µM,
all cell lines), and 8f (2.5 µM, all cell lines); p < 0.01 for compounds 5h (5 µM, all cell lines) and 8f (5 µM,
all cell lines).
To verify the selectivity of 5h and 8f towards the two enzymatic isoforms, we performed a SphK
activity assay. The principle of the method is to quantify, by luminescence, the remaining amount
of adenosine triphosphate (ATP) in solution following the kinase reaction. The luminescent signal
is inversely correlated with the kinase activity. The SphK1 competitive inhibitor PF-543 was used
as a positive control for SphK1 and as a negative control for SphK2. As shown in Figure 2A, PF-543, 5h,
and 8f tested at 10 µM, were able to inhibit SphK1 activity as demonstrated by the higher ATP levels
in solution when compared to that of the control. When tested on SphK2, only compound 5h caused
an increment of ATP levels, with respect to the control, indicating that it is able to inhibit both the
enzymes (Figure 2B).
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Figure 2. Effect of the tested compounds on the adenosine triphosphate (ATP) levels in the presence 
of SphK1 and SphK2. (A,B): ATP concentrations (µM) were measured by the Sphingosine Kinase 
Activity Assay (Echelon Biosciences) in the presence of SphK1 (A) and SphK2 (B), and tested with 
PF-543, 5h, and 8f. All the compounds were evaluated at the concentrations of 10 µM. For further 
details, see the Materials and Methods section. Data represent the mean (±SD) of two experiments 
performed in triplicate. Bars show SDs. (C,D): Percent of enzyme inhibition by PF-543, 5h, and 8f on 
SphK1 (C) and by 5h on SphK2 (D), respectively, as measured by the Sphingosine Kinase Activity 
Assay (Echelon Biosciences). 
2.4. Specific 8f Versus Aspecific 5h 
Is there a conceivable intrinsic difference between these two compounds that can rationalize the 
specificity of 8f with respect to the SphK1 isoform? In principle, it is very difficult to discuss this 
problem in terms of conformational properties of the two compounds, mainly because only the 
structure of the SphK1 isoform is known (PDB: 3VZB), whereas that of the SphK2 isoform is still 
unknown. However, it is possible to compare the molecular models of 8f and 5h in a simple 
qualitative way and draw a tentative hypothesis. 
Molecular models of 8f and 5h are shown in Figure 3 side by side, superimposed to the 
silhouette of the “J” site. It is possible to appreciate that the head of 8f has a conformation 
complementary to the shape of the active site of the SphK1 isoform, whereas the corresponding 
moiety of 5h is simpler (and shorter) and can thus adapt, in principle, to the (presumably) different 
shapes of SphK1 and SphK2 isoforms. 
Figure 2. Effect of the tested compounds on the adenosine triphosphate (ATP) levels in the presence
of SphK1 and SphK2. (A,B): ATP concentrations (µM) were measured by the Sphingosine Kinase
Activity Assay (Echelon Biosciences) in the presence of SphK1 (A) and SphK2 (B), and tested with
PF-543, 5h, and 8f. All the compounds were evaluated at the concentrations of 10 µM. For further details,
see the Materials and Methods section. Data represent the mean (±SD) of two experiments performed
in triplicate. Bars show SDs. (C,D): Percent of enzyme inhibition by PF-543, 5h, and 8f on SphK1
(C) and by 5h on SphK2 (D), respectively, as measured by the Sphingosine Kinase Activity Assay
(Echelon Biosciences).
In order to better display these results, we converted the data to percent of inhibition, obtaining the
graphs reported in Figure 2C,D. As isplayed, PF-543 was completely ineffective on SphK2 (Figure 2B)
and selectively inhibited SphK1 (Figure 2A), even if it was less effecti e than expected. Moreover,
when it was tested n A549 cells, it reduced cell density by less than 50% at 5 µM (Figure S1) showing
an antipr liferative effect lower than that of the here reported compounds. Finally, compound 8f was
able to selectively inhibit S hK1, while compound 5h showed a c mparable inhibition of both the
enzyme isoforms SphK1 and SphK2. This data proposes 5h as a dual inhibitor and might explain
the higher efficacy of 5h as an a tiproliferative agent. Several groups have reported that knockdown
of SphK1 or SphK2 has produced compensatory increases in expression of the other isoform [13].
This phenomenon supports the need for more p tent SphK1/SphK2 dual inhibitors.
2.4. Specific 8f Versus Aspecific 5h
Is there a conceivable intrinsic difference between these two compounds that can rationalize
the specificity of 8f with respect to the SphK1 isoform? In principle, it is very difficult to discuss
this problem in terms of conformational properties of the two compounds, mainly because only the
structure of the SphK1 isoform is known (PDB: 3VZB), whereas that of the SphK2 isoform is still
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unknown. However, it is possible to compare the molecular models of 8f and 5h in a simple qualitative
way and draw a tentative hypothesis.
Molecular models of 8f and 5h are shown in Figure 3 side by side, superimposed to the silhouette
of the “J” site. It is possible to appreciate that the head of 8f has a conformation complementary to the
shape of the active site of the SphK1 isoform, whereas the corresponding moiety of 5h is simpler
(and shorter) and can thus adapt, in principle, to the (presumably) different shapes of SphK1 and
SphK2 isoforms.Int. J. Mol. Sci. 2017, 18, 2332 8 of 18 
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3. Materials and Methods 
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All reagents and solvents were purchased from Sigma-Aldrich (Milan, Italy). Melting points, 
determined using a Buchi Melting Point B-540 instrument, are uncorrected and represent values 
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on an API 2000 Applied Biosystem mass spectrometer. Elemental analyses were carried out on a 
Carlo Erba model 1106; analyses indicated by the symbols of the elements were within ±0.4% of the 
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Merck silica gel 60 F254 plates with a fluorescent indicator, and the plates were visualized with UV 
light (254 nm). Preparative chromatographic purifications were performed using a silica gel column 
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B over 20 min. The column was connected to a Rheodyne model 7725 injector, a Waters 600 HPLC 
system, a Waters 486 tunable absorbance detector set to 220 nm, and a Waters 746 chart recorder. 
3.2. Synthesis of N-(aryl)-1-(hydroxyalkyl)pyrrolidine-2-carboxamide Derivatives (Compounds 2a–2g and 
3a-3g) 
3.2.1. Synthesis of N-(4-chlorophenyl)pyrrolidine-2-carboxamide (1a) 
To a solution of Boc-Pro-OH (1 mmol) and p-chloro-aniline (1 mmol) dissolved in anhydrous 
DMF (15 mL) were added TBTU (1.1 mmol), HOBt (1.1 mmol), and N, N-diisopropylethylamine 
(DIPEA) (1.1 mmol). The reaction mixture was stirred for 12 h at room temperature. After solvent 
removal, the residue was dissolved in ethyl acetate and extracted with 10% citric acid, 5% NaHCO3, 
and brine. The organic phase was dried with Na2SO4, filtered, and evaporated to dryness. The 
residue was purified on a silica gel column using DCM/MeOH (9.5/0.5 v/v) as an eluent. The 
crystallization with diethyl ether provided the Boc protected product that was dissolved in 40% TFA 
in DCM (10 mL) and the mixture was stirred at room temperature for 2 h. After evaporation of the 
Figure 3. Comparison of the molecular models of inhibitors 5h and 8f. The outline of the “J” site,
typical of the SphK1 isoform active site is superimposed to both models. In the case of the 8f model,
the outline is prolonged to show the good complementarity with the shape of the active site.
3. Materials and Methods
3.1. Chemistry
All reagents and solvents were purchased from Sigma-Aldrich (Milan, Italy). Melting points,
determined using a Buchi Melting Point B-540 instrument, are uncorrected and represent values
obtained on recrystallized or chromatographically purified material. 1H-NMR and 13C-NMR spectra
were recorded on Varian Mercury Plus 400 MHz instrument. Spectra of compounds 2a–2g and 3a–3g
were recorded in CDCl3, while those of compounds 5a–5h and 8a–8h were recorded in dimethyl
sulfoxide (DMSO)-d6. Chemical shifts are reported in ppm. The following abbreviations are used
to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), m (multiplet), bs (broad
singlet), mm (multiplet of multiplet). Mass spectra of the final products were performed on an API
2000 Applied Biosystem mass spectrometer. Elemental analyses were carried out on a Carlo Erba
model 1106; analyses indicated by the symbols of the elements were within ±0.4% of the theoretical
values. All reactions were followed by thin-layer chromatography (TLC), carried out on Merck silica
gel 60 F254 plates with a fluorescent indicator, and the plates were visualized with UV light (254 nm).
Preparative chromatographic purifications were performed using a silica gel column (Kieselgel 60).
Solutions were dried over Na2SO4 and concentrated with a Buchi R-114 rotary evaporator at low
pressure. Homogeneity of the products was assessed by analytical reversed-phase high pressure
liquid chromatography (HPLC) using a Macherey-Nagel Nucleosil 100-5 C18 (5 µm, 4 × 125 mm),
applying the following gradient of 0.1% (v/v) trifluoroacetic acid (TFA) in H2O (solvent A) and 0.1%
TFA (v/v) in acetonitrile (solvent B) at a constant flow of 1 mL/min: (i) gradient 30–60% B over 20 min.
The column was connected to a Rheodyne model 7725 injector, a Waters 600 HPLC system, a Waters
486 tunable absorbance detector set to 220 nm, and a Waters 746 chart recorder.
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3.2. Synthesis of N-(aryl)-1-(hydroxyalkyl)pyrrolidine-2-carboxamide Derivatives (Compounds 2a–2g and
3a–3g)
3.2.1. Synthesis of N-(4-chlorophenyl)pyrrolidine-2-carboxamide (1a)
To a solution of Boc-Pro-OH (1 mmol) and p-chloro-aniline (1 mmol) dissolved in anhydrous DMF
(15 mL) were added TBTU (1.1 mmol), HOBt (1.1 mmol), and N, N-diisopropylethylamine (DIPEA)
(1.1 mmol). The reaction mixture was stirred for 12 h at room temperature. After solvent removal,
the residue was dissolved in ethyl acetate and extracted with 10% citric acid, 5% NaHCO3, and brine.
The organic phase was dried with Na2SO4, filtered, and evaporated to dryness. The residue was
purified on a silica gel column using DCM/MeOH (9.5/0.5 v/v) as an eluent. The crystallization with
diethyl ether provided the Boc protected product that was dissolved in 40% TFA in DCM (10 mL) and
the mixture was stirred at room temperature for 2 h. After evaporation of the solvent, the desired
product 1a was obtained as a white solid by crystallization with diethyl ether (yield 47%, calculated
on two steps).
Using the above described procedure intermediates 1b–1g were prepared starting from
4-hexylaniline (1b), 4-heptylaniline (1c), 4-octylaniline (1d), α-naphtylamine (1e), 2-aminobiphenyl (1f),
and 4-aminobiphenyl (1g).
3.2.2. N-(4-chlorophenyl)-1-(2-hydroxyethyl)pyrrolidine-2-carboxamide (2a)
A solution of 2-bromoethanol (1 mmol) and NaI (1.5 mmol) dissolved in 15 mL of DMF was
stirred under reflux for 30 min. Then, a solution of 1a (1 mmol) and K2CO3 (1.5 mmol) in 10 mL
of DMF was added drop wise. After 12 h, the reaction mixture was cooled at room temperature,
the solid was filtered off, and the solvent was evaporated under vacuum. The obtained residue was
dissolved in ethyl acetate and the solution was extracted with brine. The organic phase was then dried
with Na2SO4, filtered, and evaporated under vacuum, furnishing an oily residue. This residue was
purified by chromatography on a silica gel column using a mixture of DCM/MeOH (9.5/0.5; v/v)
as an eluent, thus obtaining the final product 2a as an oil. Yield: 67%. 1H-NMR δ = 9.77 (s, 1H, -NH),
7.54 (d, J = 8.1 Hz, 2H), 7.19 (d, J = 8.1 Hz, 2H), 3.76–3.71 (m, 1H), 3.66–3.63 (m, 1H), 3.27–3.26 (m, 1H),
3.17–3.15 (m, 1H), 2.85–2.80 (m, 1H), 2.70–2.66 (m, 1H), 2.40–2.36 (m, 1H), 2.22–2.17 (m, 1H), 1.98–1.96
(m, 1H), 1.79–1.73 (m, 2H); 13C-NMR δ = 173.45, 136.99, 131.47, 129.11, 120.84, 68.18, 61.07, 57.89, 54.32,
30.87, 24.70. ESI-MS calculated: 268.74; Found: 269.3 [M + H]+. Anal. (C13H17ClN2O2), C, H, N.
3.2.3. N-(4-hexylphenyl)-1-(2-hydroxyethyl)pyrrolidine-2-carboxamide (2b)
Compound 2b was obtained following the procedure described for 2a, starting from 1b and
2-bromoethanol. Yield: 60%; oil. 1H-NMR δ = 9.65 (s, 1H, -NH), 7.53 (d, J = 8.1 Hz, 2H),
7.11 (d, J = 8.1 Hz, 2H), 3.78–3.75 (m, 1H), 3.72–3.70 (m, 1H), 3.33–3.31 (m, 1H), 3.24–3.20 (m, 1H),
2.88 (m, 1H), 2.74–2.71 (m, 1H), 2.56 (t, J = 7.0 Hz, J = 7.7 Hz, 2H), 2.46–2.43 (m, 1H), 2.20–2.25 (m, 1H),
2.01–2.05 (m, 1H), 1.82–1.80 (m, 2H), 1.28 (bs, 8H), 0.87 (t, J = 7.0 Hz, 3H); 13C-NMR δ = 173.24, 138.85,
135.88, 129.02, 119.54, 68.21, 61.09, 57.93, 54.36, 35.62, 31.97, 31.83, 30.88, 29.14, 24.65, 22.87, 14.38.
ESI-MS calculated: 318.45; Found: 319.3 [M + H]+. Anal. (C19H30N2O2), C, H, N.
3.2.4. N-(4-heptylphenyl)-1-(2-hydroxyethyl)pyrrolidine-2-carboxamide (2c)
Compound 2c was obtained following the procedure described for 2a, starting from 1c and
2-bromoethanol. Yield: 54%; oil. 1H-NMR δ = 9.62 (s, 1H, -NH), 7.56 (d, J = 7.8 Hz, 2H),
7.11 (d, J = 7.8 Hz, 2H), 3.86–3.76 (m, 3H), 3.34–3.28 (m, 1H), 3.21–3.13 (m, 1H), 2.58 (t, J = 7.0 Hz,
2H), 2.45–2.39 (m, 1H), 2.09–2.01 (m, 1H), 2.03–1.97 (m, 1H), 1.78–1.73 (m, 2H), 1.69–1.65 (m, 1H),
1.52–1.45 (m, 2H), 1.30 (bs, 8H), 0.87 (t, J = 7.0 Hz, 3H); 13C-NMR δ = 172.65, 138.85, 135.41, 129.07,
119.50, 68.24, 61.10, 58.01, 54.37, 35.36, 31.99, 31.77, 30.87, 29.68, 29.14, 24.64, 22.64, 14.07. ESI-MS
calculated: 332.48; Found: 333.4 [M + H]+. Anal. (C20H32N2O2), C, H, N.
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3.2.5. N-(4-octylphenyl)-1-(2-hydroxyethyl)pyrrolidine-2-carboxamide (2d)
Compound 2d was obtained following the procedure described for 2a, starting from 1d and
2-bromoethanol. Yield: 73%; oil. 1H-NMR δ = 9.62 (s, 1H, -NH), 7.53 (d, J = 8.1 Hz, 2H),
7.10 (d, J = 8.1 Hz, 2H), 3.80–3.75 (m, 1H), 3.71–3.70 (m, 1H), 3.32–3.30 (m, 1H), 3.23–3.20 (m, 1H),
2.88 (m, 1H), 2.74–2.71 (m, 1H), 2.55 (t, J = 7.3 Hz, 2H), 2.47–2.41 (m, 1H), 2.24–2.22 (m, 1H), 2.03–2.00
(m, 1H), 1.82–1.80 (m, 2H), 1.49–1.52 (m, 2H), 1.26 (bs, 10H), 0.86 (t, J = 7.0 Hz, 3H); 13C-NMR δ = 173.04,
138.81, 135.90, 128.99, 119.52, 68.29, 61.13, 57.95, 54.38, 35.60, 32.10, 31.81, 30.87, 29.69, 29.49, 29.45,
24.63, 22.88, 14.32. ESI-MS calculated: 332.48; Found: 333.4 [M + H]+. Anal. (C21H34N2O2), C, H, N.
3.2.6. 1-(2-hydroxyethyl)-N-(naphthalen-1-yl)pyrrolidine-2-carboxamide (2e)
Compound 2e was obtained following the procedure described for 2a, starting from 1e and
2-bromoethanol. Yield: 66%; oil. 1H-NMR δ = 10.23 (s, 1H, –NH), 8.23 (d, J = 7.3 Hz, 1H),
8.01 (d, J = 7.7 Hz, 1H), 7.86 (d, 7.7 Hz, 1H), 7.65 (d, J = 8.1 Hz, 1H), 7.53–7.45 (m, 3H), 3.87–3.77
(m, 2H), 3.45–3.44 (m, 1H), 3.39 (dd, J = 13.9, 4.0 Hz, 1H), 3.05–3.00 (m, 1H), 2.82–2.77 (m, 1H), 2.56–2.50
(m, 1H), 2.36–2.26 (m, 1H), 2.13–2.10 (m, 1H), 1.93–1.90 (m, 2H); 13C-NMR δ = 173.65, 134.30, 132.90,
128.90, 126.54, 126.29, 126.16, 126.04,124.95, 120.91, 118.56, 68.90, 61.29, 58.26, 54.62, 31.09, 24.87. ESI-MS
calculated: 284.15; Found: 285.3 [M + H]+. Anal. (C17H20N2O2), C, H, N.
3.2.7. N-(biphenyl-2-yl)-1-(2-hydroxyethyl)pyrrolidine-2-carboxamide (2f)
Compound 2f was obtained following the procedure described for 2a, starting from 1f and
2-bromoethanol. Yield: 72%; oil. 1H-NMR δ = 9.67 (s, 1H,–NH), 8.45 (d, J = 8.1 Hz, 1H),
7.50 (d, J = 7.3 Hz, 2H), 7.45–7.24 (m, 5H), 7.18 (t, J = 6.9 Hz, 1H), 3.28–3.25 (m, 3H),
3.19 (d, J = 9.9 Hz, 1H), 2.97–2.93 (m, 2H), 2.68–2.65 (m, 1H), 2.48–2.45 (m, 1H), 2.31–2.29 (m, 1H),
2.16–2.14 (m, 1H), 2.09–2.00 (m, 1H), 1.65–1.63 (m, 1H); 13C-NMR δ = 173.14, 139.08, 135.17, 132.25,
130.17, 129.80, 128.98, 128.80, 127.95, 124.23, 120.60, 68.88, 61.14, 58.16, 54.27, 30.85, 24.95. ESI-MS
calculated: 310.39; Found: 311.4 [M + H]+. Anal. (C19H22N2O2), C, H, N.
3.2.8. N-(biphenyl-4-yl)-1-(2-hydroxyethyl)pyrrolidine-2-carboxamide (2g)
Compound 2g was obtained following the procedure described for 2a, starting from 1g and
2-bromoethanol. Yield: 69%; oil. 1H-NMR δ = 9.83 (s, 1H, –NH), 7.73 (d, J = 8.4 Hz, 2H),
7.57–7.53 (m, 4H), 7.43 (t, J = 7.3, 7.7 Hz, 2H), 7.33 (t, J = 7.3 Hz, 1H), 3.81–3.78 (m, 1H),
3.75–3.73 (m, 1H), 3.38–3.36 (m, 1H), 3.29–3.28 (m, 1H), 2.92–2.90 (m, 1H), 2.80–2.78 (m, 1H), 2.49–2.47
(m, 1H), 2.30–2.26 (m, 1H), 2.07–2.05 (m, 1H), 1.86–1.82 (m, 2H); 13C-NMR δ = 173.36, 140.92, 137.63,
136.95, 128.97, 128.80, 127.76, 127.04, 119.88, 68.28, 61.09, 57.93, 54.38, 30.89, 24.67. ESI-MS calculated:
310.39; Found: 311.3 [M + H]+. Anal. (C19H22N2O2), C, H, N.
3.2.9. N-(4-chlorophenyl)-1-(3-hydroxypropyl)pyrrolidine-2-carboxamide (3a)
Compound 3a was obtained following the procedure described for 2a, starting from 1a and
3-bromopropanol. Yield: 82%; oil. 1H-NMR δ = 9.47 (s, 1H, –NH), 7.60 (d, J = 8.1 Hz, 2H),
7.27 (d, J = 7.7 Hz, 2H), 3.83–3.76 (m, 2H), 3.30–3.27 (m, 1H), 3.17–3.14 (m, 1H), 2.93–2.86 (m, 1H),
2.61–2.58 (m, 1H), 2.40–2.33 (m, 1H), 2.30–2.20 (m, 1H), 1.98–1.96 (m, 1H), 1.83–1.78 (m, 4H); 13C-NMR
δ = 173.20, 136.83, 131.47, 129.13, 120.86, 68.92, 61.39, 53.95, 53.14, 31.26, 30.71, 24.36. ESI-MS calculated:
282.77; Found: 283.3 [M + H]+. Anal. (C14H19ClN2O2), C, H, N.
3.2.10. N-(4-hexylphenyl)-1-(3-hydroxypropyl)pyrrolidine-2-carboxamide (3b)
Compound 3b was obtained following the procedure described for 2a, starting from 1b and
3-bromopropanol. Yield: 56%; oil. 1H-NMR δ = 9.65 (s, 1H, –NH), 7.53 (d, J = 8.1 Hz, 2H),
7.11 (d, J = 8.1 Hz, 2H), 3.78–3.75 (m, 2H), 3.72–3.70 (m, 1H), 3.33–3.31 (m, 1H), 3.24–3.20 (m, 1H),
2.88 (t, 2H), 2.74–2.71 (m, 1H), 2.56 (t, 2H), 2.46–2.43 (m, 1H), 2.20–2.25 (m, 1H), 2.01–2.05 (m, 1H),
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1.82–1.80 (m, 1H), 1.28 (bs, 8H), 0.87 (t, 3H); 13C-NMR δ = 173.24, 138.98, 135.41, 128.89, 119.37, 68.21,
61.09, 53.89, 53.03, 35.35, 31.71, 31.51, 30.35, 29.68, 28.86, 23.93, 22.59, 14.08. ESI-MS calculated: 332.48;
Found: 333.3 [M + H]+. Anal. (C20H32N2O2), C, H, N.
3.2.11. N-(4-heptylphenyl)-1-(3-hydroxypropyl)pyrrolidine-2-carboxamide (3c)
Compound 3c was obtained following the procedure described for 2a, starting from 1c and
3-bromopropanol. Yield: 84%; oil. 1H-NMR δ = 9.62 (s, 1H, –NH), 7.58 (d, J = 7.8 Hz, 2H),
7.12 (d, J = 7.8 Hz, 2H), 3.80–3.76 (m, 3H), 3.49–3.46 (m, 1H), 3.11–3.07 (m, 1H), 2.55 (t, J = 7.0 Hz,
2H), 2.47–2.40 (m, 1H), 2.14–2.09 (m, 1H), 2.03–1.97 (m, 1H), 1.82–1.80 (m, 2H), 1.70–1.66 (m, 1H),
1.58–1.55 (m, 2H), 1.30 (bs, 10H), 0.87 (t, J = 7.0 Hz, 3H); 13C-NMR δ = 172.80, 138.48, 135.41, 129.07,
119.50, 68.24, 61.08, 53.80, 53.13, 35.36, 31.50, 30.52, 29.67, 29.45, 29.24, 29.19, 24.14, 22.68, 14.07. ESI-MS
calculated: 346.51; Found: 347.4 [M + H]+. Anal. (C21H34N2O2), C, H, N.
3.2.12. N-(4-octylphenyl)-1-(3-hydroxypropyl)pyrrolidine-2-carboxamide (3d)
Compound 3d was obtained following the procedure described for 2a, starting from 1d and
3-bromopropanol. Yield: 61%; oil. 1H-NMR δ = 9.62 (s, 1H, –NH), 7.50 (d, J = 7.8 Hz, 2H),
7.13 (d, J = 7.8 Hz, 2H), 3.90–3.85 (m, 2H), 3.76–3.72 (m, 1H), 3.64–3.62 (m, 1H), 3.50–3.49 (m, 1H),
3.26–3.24 (m, 1H), 3.12–3.10 (m, 1H), 3.02–2.99 (m, 1H), 2.53 (t, J = 6.6 Hz, 2H), 2.03–2.00 (m, 1H),
1.92–1.94 (m, 2H), 1.76–1.78 (m, 2H), 1.49–1.52 (m, 2H), 1.26 (bs, 10H), 0.86 (t, J = 7.0 Hz, 3H); 13C-NMR
δ = 172.93, 138.99, 135.48, 128.87, 119.45, 68.54, 60.82, 53.80, 52.88, 35.35, 31.86, 31.55, 30.52, 29.67, 29.45,
29.24, 29.19, 24.15, 22.64, 14.08. ESI-MS calculated: 360.53; Found: 361.6 [M + H]+. Anal. (C22H36N2O2),
C, H, N.
3.2.13. 1-(3-hydroxypropyl)-N-(naphthalen-1-yl)pyrrolidine-2-carboxamide (3e)
Compound 3e was obtained following the procedure described for 2a, starting from 1e and
3-bromopropanol. Yield: 52%; oil. 1H-NMR δ = 10.11 (s, 1H, –NH), 8.20 (d, J = 7.3 Hz,
1H), 7.87–7.84 (m, 2H), 7.66 (d, J = 8.1 Hz, 1H), 7.55–7.46 (m, 3H), 3.77–3.74 (m, 2H), 3.42–3.40
(m, 1H), 3.35 (dd, J = 13.9, 4.0 Hz, 1H), 3.02–2.96 (m, 1H), 2.76–2.70 (m, 1H), 2.52–2.46 (m, 1H),
2.34–2.29 (m, 1H), 2.11–2.08 (m, 1H), 1.91–1.88 (m, 4H); 13C-NMR δ = 173.52, 134.32, 132.72, 129.08,
126.54, 126.38, 126.23, 126.07, 125.01, 120.42, 118.76, 69.09, 61.24, 54.44, 53.40, 32.00, 31.02, 24.79. ESI-MS
calculated: 298.29; Found: 299.1 [M + H]+. Anal. (C18H22N2O2), C, H, N.
3.2.14. N-(biphenyl-2-yl)-1-(3-hydroxypropyl)pyrrolidine-2-carboxamide (3f)
Compound 3f was obtained following the procedure described for 2a, starting from 1f and
3-bromopropanol. Yield: 62%; oil. 1H-NMR δ = 9.71 (s, 1H, –NH), 8.37 (d, J = 8.1 Hz, 1H),
7.46 (d, J = 6.6 Hz, 2H), 7.39–7.23 (m, 5H), 7.18 (t, J = 6.9 Hz, 1H), 3.32–3.16 (m, 3H), 2.96–2.91 (m, 2H),
2.58–2.55 (m, 1H), 2.43–2.40 (m, 1H), 2.28–2.24 (m, 1H), 2.16–2.14 (m, 1H), 2.02–1.94 (m, 1H), 1.78–1.75
(m, 2H), 1.63–1.60 (m, 1H); 13C-NMR δ = 173.14, 139.10, 135.17, 132.25, 130.16, 129.63, 128.98, 128.80,
127.95, 124.33, 120.61, 68.90, 61.15, 54.24, 53.38, 31.25, 30.85, 24.95. ESI-MS calculated: 324.42; Found:
325.4 [M + H]+. Anal. (C20H24N2O2), C, H, N.
3.2.15. N-(biphenyl-4-yl)-1-(3-hydroxypropyl)pyrrolidine-2-carboxamide (3g)
Compound 3g was obtained following the procedure described for 2a, starting from 1g and
3-bromopropanol. Yield: 54%; oil. 1H-NMR δ = 9.76 (s, 1H, –NH), 7.74 (d, J = 8.2 Hz,
2H), 7.55–7.53 (m, 4H), 7.42 (t, J = 7.4, 7.0 Hz, 2H), 7.33 (t, J = 7.4 Hz, 1H), 3.82–3.78 (m, 2H),
3.65–3.63 (m, 1H), 3.48–3.42 (m, 1H), 3.06–3.00 (m, 1H), 2.87–2.84 (m, 2H), 2.62–2.60 (m, 1H), 2.40–2.37
(m, 1H), 2.05–2.03 (m, 1H), 1.90–1.83 (m, 3H); 13C-NMR δ = 173.36, 140.48, 137.13, 137.05, 128.77, 127.55,
127.09, 126.80, 119.99, 68.54, 61.02, 54.04, 53.37, 30.45, 29.68, 23.91. ESI-MS calculated: 324.42; Found:
325.5 [M + H]+. Anal. (C20H24N2O2), C, H, N.
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3.3. Synthesis of 1,4-Disubstituted 1,2,3-Triazoles 5a–5h
3.3.1. Synthesis of 1-Azido-4-octylbenzene (4)
One mmol of 4-octylaniline was suspended in 1 mL of H2O and 0.370 mL of concentrated HCl.
To the reaction mixture, stirred and cooled to 0 ◦C, a solution of NaNO2 (1.04 mmol) in 1 mL of H2O
was then added dropwise. After 30 min, the reaction mixture containing the formed diazonium salt,
was poured into a solution of sodium azide (1.12 mmol) in 0.2 mL of H2O and ice. The formation
of an intense foam, due to the release of N2, was observed. The mixture was stirred for 12 h, then the
solution was extracted with DCM (three times) and the collected organic phases were dried with
Na2SO4. Evaporation of the solvent left the desired intermediate 4, with a yield of 68%.
3.3.2. Synthesis of (1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)methanol (5a)
2-Propin-1-ol (1 mmol) and 4 (1 mmol) were suspended in a 1:1 mixture of water and tert-butyl
alcohol (12 mL). Sodium ascorbate (0.05 mmol) and copper sulfate pentahydrate (0.01 mmol) dissolved
in 6 mL of H2O:tBuOH (1/1, v/v) were added. The heterogeneous mixture was stirred vigorously
for 48 h, at which point it cleared and TLC analysis indicated complete consumption of the reactants.
The reaction mixture was diluted with water (15 mL), cooled in ice, and the white precipitate was
collected by filtration. After washing the precipitate with cold water (2 × 5 mL), it was dried under
vacuum to afford the pure product as an off-white powder. Yield: 85%; mp 69–70 ◦C. 1H-NMR δ = 8.59
(s, 1H), 7.76 (d, J = 7.0 Hz, 2H), 7.37 (d, J = 6.6 Hz, 2H), 5.27 (s, 2H), 4.58 (s, 1H, –OH), 2.61 (m, J = 7.8 Hz,
J = 6.3 Hz, 2H), 1.57 (m, 2H), 1.26 (bs, 10 H), 0.82 (t, J = 6.3 Hz, J = 7.0 Hz, 3H). 13C-NMR δ = 149.66,
143.59, 135.36, 130.24, 121.55, 120.56, 55.65, 35.24, 31.94, 31.48, 29.49, 29.33, 29.29, 22.75, 14.63. ESI-MS
calculated: 287.40; Found: 288.0 [M + H]+. Anal. (C17H25N3O), C, H, N.
3.3.3. 2-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)ethanol (5b)
Compound 5b was obtained following the procedure described for 5a, starting from 4 and
3-butyn-1-ol. Yield: 90%; mp 90–91 ◦C. 1H-NMR δ = 8.48 (s, 1H), 7.74 (d, J = 7.7 Hz, 2H),
7.37 (d, J = 7.7 Hz, 2H), 4.72 (s, 1H, –OH), 3.68 (m, 2H), 2.84 (t, J = 6.2 Hz, J = 6.6 Hz, 2H), 2.61
(t, J = 6.9 Hz, 2H), 1.58 (m, 2H), 1.27 (bs, 10 H), 0.83 (t, J = 6.3 Hz, J = 7.0 Hz, 3H). 13C-NMR δ = 146.17,
143.44, 135.38, 130.23, 121.30, 120.44, 60.93, 35.24, 31.95, 31.47, 29.88, 29.49, 29.33, 29.28, 22.76, 14.63.
ESI-MS calculated: 301.43; Found: 302.1 [M + H]+. Anal. (C18H27N3O) C, H, N.
3.3.4. 3-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)propan-1-ol (5c)
Compound 5c was obtained following the procedure described for 5a, starting from 4 and
4-pentyn-1-ol. Yield: 77%; mp 59–60 ◦C. 1H-NMR δ = 8.48 (s, 1H), 7.74 (d, J = 8.2 Hz, 2H),
7.37 (d, J = 7.7 Hz, 2H), 4.50 (t, 1H, –OH, J = 5.1 Hz), 3.48 (m, 2H), 2.73 (t, 2H, J = 7.4 Hz, J = 7.8 Hz),
2.63 (t, 2H, J = 7.4 Hz, J = 7.8 Hz), 1.82 (m, 2H), 1.57 (m, 2H), 1.27 (bs, 10 H), 0.85 (t, 3H, J = 6.3 Hz,
J = 6.6 Hz). 13C-NMR δ = 148.35, 143.17, 135.20, 129.97, 120.43, 120.18, 60.46, 34.99, 32.58, 31.70,
31.25, 29.25, 29.09, 29.04, 22.52, 22.14, 14.40. ESI-MS calculated: 315.45; Found: 316.1 [M + H]+;
338.3 [M + Na]+; 354.3 [M + K]+. Anal. (C19H29N3O), C, H, N.
3.3.5. 2-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)pyridine (5d)
Compound 5d was obtained following the procedure described for 5a, starting from 4 and
2-ethynylpyridine. Yield: 83%; mp 85–86 ◦C. 1H-NMR δ = 9.25 (s, 1H), 8.64 (d, J = 3.9 Hz, 1H),
8.10 (d, J = 7.8 Hz, 1H), 7.92 (m, 3H), 7.41 (m, 3H), 2.65 (t, J = 7.4 Hz, J = 7.8 Hz, 2H), 1.58 (m, 2H),
1.28 (bs, 10 H), 0.83 (t, J = 6.3 Hz, J = 6.6 Hz, 3H). 13C-NMR δ = 150.10, 150.03, 148.54, 143.78, 137.77,
134.93, 130.05, 123.74, 121.58, 120.57, 120.21, 35.03, 31.71, 31.24, 29.26, 29.10, 29.06, 22.52, 14.39. ESI-MS
calculated: 334.46; Found: 335.2 [M + H]+. Anal. (C21H26N4), C, H, N.
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3.3.6. 3-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)pyridine (5e)
Compound 5e was obtained following the procedure described for 5a, starting from 4 and
3-ethynylpyridine. Yield: 85%; mp 125–126 ◦C. 1H-NMR δ = 9.35 (s, 1H), 9.12 (s, 1H), 8.57 (m, 2H),
8.29 (d, J = 7.7 Hz, 1H), 7.81 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 8.1 Hz, 2H), 2.64 (t, J = 7.4 Hz, J = 7.8 Hz,
2H), 1.59 (m, 2H), 1.27 (bs, 10 H), 0.83 (t, J = 6.3 Hz, J = 6.6 Hz, 3H). 13C-NMR δ = 149.7, 146.97, 144.87,
143.88, 134.90, 132.97, 130.13, 124.54, 120.78, 120.50, 79.62, 35.05, 31.71, 31.25, 29.26, 29.11, 22.53, 14.40.
ESI-MS calculated: 334.46; Found: 335.2 [M + H]+. Anal. (C21H26N4), C, H, N.
3.3.7. 1-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)cyclohexanol (5f)
Compound 5f was obtained following the procedure described for 5a, starting from 4 and
1-ethynylcyclohexanol. Yield: 78%; mp 119–120 ◦C. 1H-NMR δ = 8.51 (s, 1H), 7.77 (d, J = 8.1 Hz,
2H), 7.36 (d, J = 8.1 Hz, 2H), 4.94 (s, 1H), 2.62 (t, J = 7.0 Hz, J = 7.7 Hz, 2H), 1.94–1.63 (mm, 6H),
1.57 (m, 2H), 1.43 (m, 4H), 1.26 (bs, 10 H), 0.82 (t, J = 6.3 Hz, J = 6.6 Hz, 3H). 13C-NMR δ = 157.35,
143.41, 135.46, 130.21, 120.44, 119.85, 68.64, 38.37, 35.24, 31.95, 31.47, 29.49, 29.30, 25.93, 22.76, 22.38,
14.63. ESI-MS calculated: 355.52; Found: 356.4 [M + H]+. Anal. (C22H33N3O), C, H, N.
3.3.8. (4-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)phenyl)methanol (5g)
Compound 5g was obtained following the procedure described for 5a, starting from 4 and
(4-ethynylphenyl)methanol. Yield: 87%; mp 160–161 ◦C. 1H-NMR δ = 9.20 (s, 1H), 7.89 (d, J = 7.0 Hz,
2H), 7.83 (d, J = 7.4 Hz, 2H), 7.43 (d, J = 7.4 Hz, 4H) 5.23 (s, 1H, -OH), 4.53 (d, J = 4.7 Hz, 2H),
2.66 (t, J = 7.0 Hz, J = 6.6 Hz, 2H), 1.60 (m, 2H), 1.28 (bs, 10 H), 0.84 (t, J = 6.3 Hz, J = 6.6 Hz, 3H).
13C-NMR δ = 147.67, 143.60, 143.07, 135.03, 130.06, 129.18, 127.41, 125.52, 120.34, 119.70, 63.10, 35.03,
31.70, 31.24, 29.25, 29.10, 29.06, 22.51, 14.39. ESI-MS calculated: 363.50; Found: 364.1 [M + H]+. Anal.
(C23H29N3O), C, H, N.
3.3.9. 3-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)phenol (5h)
Compound 5h was obtained following the procedure described for 5a, starting from 4 and
2-ethynylphenol. Yield: 78%; mp 126–127 ◦C. 1H-NMR δ = 9.57 (s, 1H, –OH), 9.15 (s, 1H),
7.82 (d, J = 7.3 Hz, 2H), 7.41 (d, J = 7.4 Hz, 2H), 7.35 (s, 1H), 7.32 (d, J = 6.6 Hz, 1H), 7.27 (t, J = 7.9 Hz,
J = 6.3 Hz, J = 7.0 Hz, 1H), 6.75 (d, J = 7.4 Hz, 1H), 2.63 (t, J = 7.0 Hz, J = 6.6 Hz, 2H), 1.58 (m, 2H),
1.27 (bs, 10 H), 0.83 (t, J = 6.3 Hz, J = 6.6 Hz, 3H). 13C-NMR δ = 158.27, 147.75, 143.59, 135.03, 131.96,
130.45, 130.05, 120.37, 119.86, 116.67, 115.67, 112.53, 35.03, 31.71, 31.25, 29.26, 29.10, 29.05, 22.52, 14.39.
ESI-MS calculated: 349.42; Found: 350.2 [M + H]+. Anal. (C22H27N3O), C, H, N.
3.4. Synthesis of 1,4-Disubstituted 1,2,3-Triazoles 8a–8h
3.4.1. Synthesis of 2-Bromo-N-(4-octylphenyl)acetamide (6)
The 2-bromoacetyl bromide (1.3 mmol), dissolved in toluene (5 mL), was added dropwise
to a solution of 4-octyl-aniline (1 mmol) in toluene (5 mL). The reaction mixture was heated to 110 ◦C,
and after 4 h, ethyl acetate was added and the resulting solution was extracted with brine (three times).
The organic phase, dried with Na2SO4, was filtered and evaporated to dryness. The crystallization
with ethyl ether provided the desired product 6 (yield: 83%).
3.4.2. Synthesis of 2-Azido-N-(4-octylphenyl)acetamide (7)
The intermediate 6 (1 mmol) was dissolved in ethanol (10 mL), sodium azide (1.25 mmol) was
added, and the reaction was refluxed for 2 h and 30 min. Then, it was cooled and diethyl ether
(10 mL) was added. The precipitated NaBr was filtered off and the filtrate was evaporated to dryness.
The residue was crystallized with hexane providing the desired product with 7 (yield: 86%).
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3.4.3. 2-(4-(Hydroxymethyl)-1H-1,2,3-triazol-1-yl)-N-(4-octylphenyl)acetamide (8a)
Compound 8a was obtained following the procedure described for 5a, starting from 7 and
2-propin-1-ol. Yield: 75%; mp 171–172 ◦C. 1H-NMR δ = 10.34 (s, 1H, –NH), 7.95 (s, 1H),
7.46 (d, J = 6.2 Hz, 2H), 7.12 (d, J = 6.3 Hz, 2H), 5.26 (s, 2H), 5.18 (s, 1H, –OH), 4.52 (s, 2H), 2.48 (t, 2H,
J = 7.8 Hz, J = 6.3 Hz), 1.51 (m, 2H), 1.24 (bs, 10 H), 0.83 (t, 3H, J = 6.3 Hz, J = 7.0 Hz). 13C-NMR
δ = 169.46, 153.23, 143.19, 141.54, 134.03, 129.76, 124.66, 60.47, 57.52, 39.97, 36.69, 36.40, 34.25, 34.09,
34.03, 27.51, 19.38. ESI-MS calculated: 344.45; Found: 345.5 [M + H]+. Anal. (C19H28N4O2), C, H, N.
3.4.4. 2-(4-(2-Hydroxyethyl)-1H-1,2,3-triazol-1-yl)-N-(4-octylphenyl)acetamide (8b)
Compound 8b was obtained following the procedure described for 5a, starting from 7 and
3-butyn-1-ol. Yield: 80%; mp 170–171 ◦C. 1H-NMR δ = 10.32 (s, 1H, –NH), 7.85 (s, 1H),
7.45 (d, J = 7.0 Hz, 2H), 7.12 (d, J = 7.0 Hz, 2H), 5.21 (s, 2H), 4.67 (s, 1H, –OH), 3.63 (m, 2H), 2.77 (t, 2H,
J = 6.6 Hz, J = 6.2 Hz), 2.49 (t, 2H, J = 7.8 Hz, J = 6.3 Hz), 1.51 (m, 2H), 1.23 (bs, 10 H), 0.82 (t, 3H,
J = 6.3 Hz, J = 7.0 Hz). 13C-NMR δ = 164.50, 144.64, 138.19, 136.54, 129.04, 124.46, 119.67, 60.84, 52.51,
34.98, 31.70, 31.40, 29.59, 29.26, 29.10, 29.04, 22.51, 14.39. ESI-MS calculated: 358.48; Found: 359.3
[M + H]+. Anal. (C20H30N4O2), C, H, N.
3.4.5. 2-(4-(3-Hydroxypropyl)-1H-1,2,3-triazol-1-yl)-N-(4-octylphenyl)acetamide (8c)
Compound 8c was obtained following the procedure described for 5a, starting from 7 and
4-pentyn-1-ol. Yield: 82%; mp 171–172 ◦C. 1H-NMR δ = 10.30 (s, 1H, –NH), 7.81 (s, 1H),
7.43 (d, J = 7.0 Hz, 2H), 7.10 (d, J = 7.0 Hz, 2H), 5.19 (s, 2H), 4.44 (s, 1H, –OH), 3.40 (m, 2H), 2.62 (t, 2H,
J = 7.4 Hz, J = 7.8 Hz), 1.71 (t, 2H, J = 7.4 Hz, J = 7.8 Hz), 1.49 (m, 2H), 1.21 (bs, 10 H), 0.81 (t, 3H,
J = 6.3 Hz, J = 7.0 Hz). 13C-NMR δ = 164.53, 146.99, 138.19, 136.54, 129.03, 123.88, 119.67, 60.49, 52.50,
34.98, 32.74, 31.70, 31.40, 29.26, 29.10, 29.04, 22.51, 22.07, 14.39. ESI-MS calculated: 372.50; Found: 373.3
[M + H]+. Anal. (C21H32N4O2), C, H, N.
3.4.6. N-(4-octylphenyl)-2-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)acetamide (8d)
Compound 8d was obtained following the procedure described for 5a, starting from 7 and
2-ethynylpyridine. Yield: 78%; mp 199–200 ◦C. 1H-NMR δ = 10.40 (s, 1H, –NH), 8.59 (s, 1H),
8.04 (d, J = 7.7 Hz, 1H), 7.91 (m, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.35 (t, 1H, J = 5.5 Hz, J = 6.2 Hz),
7.13 (d, J = 8.1 Hz, 2H), 5.38 (s, 2H), 2.51 (t, 2H, J = 7.8 Hz, J = 6.3 Hz), 1.51 (m, 2H), 1.24 (bs, 10 H),
0.84 (t, 3H, J = 6.3 Hz, J = 7.0 Hz). 13C-NMR δ = 164.53, 150.68, 150.35, 147.74, 138.49, 137.89, 136.76,
129.30, 125.65, 123.63, 120.08, 119.96, 52.99, 35.23, 31.94, 31.64, 29.50, 29.34, 29.28, 22.75, 14.63. ESI-MS
calculated: 391.51; Found: 392.2 [M + H]+. Anal. (C23H29N5O), C, H, N.
3.4.7. N-(4-octylphenyl)-2-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)acetamide (8e)
Compound 8e was obtained following the procedure described for 5a, starting from 7 and
3-ethynylpyridine. Yield: 85%; mp 196–197 ◦C. 1H-NMR δ = 10.42 (s, 1H, –NH), 9.06 (s, 1H), 8.71 (s, 1H),
8.53 (m, 2H), 8.23 (d, J = 7.7 Hz, 1H), 7.47 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 5.37 (s, 2H),
2.51 (t, 2H, J = 7.8 Hz, J = 6.3 Hz), 1.51 (m, 2H), 1.23 (bs, 10 H), 0.84 (t, 3H, J = 6.3 Hz, J = 7.0 Hz).
13C-NMR δ = 164.48, 149.57, 147.04, 144.10, 138.55, 136.72, 133.09, 129.31, 124.72, 124.42, 119.97, 94.57,
53.11, 35.21, 31.93, 31.63, 29.49, 29.33, 29.27, 22.75, 14.63. ESI-MS calculated: 391.51; Found: 392.1
[M + H]+. Anal. (C23H29N5O), C, H, N.
3.4.8. 2-(4-(1-Hydroxycyclohexyl)-1H-1,2,3-triazol-1-yl)-N-(4-octylphenyl)acetamide (8f)
Compound 8f was obtained following the procedure described for 5a, starting from 7 and
1-ethynylcyclohexanol. Yield: 83%; mp 154–155 ◦C. 1H-NMR δ = 10.33 (s, 1H, –NH), 7.86 (s, 1H),
7.46 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 8.2 Hz, 2H), 5.23 (s, 2H), 4.86 (s, 1H, –OH), 2.51 (t, 2H, J = 7.8 Hz,
J = 6.3 Hz), 1.85–1.64 (mm, 6H), 1.51 (m, 2H), 1.41 (m, 4H), 1.24 (bs, 10 H), 0.83 (t, 3H, J = 6.3 Hz,
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J = 7.0 Hz). 13C-NMR δ = 164.51, 156.08, 138.19, 136.57, 129.04, 122.97, 119.65, 68.44, 52.55, 38.29, 34.98,
31.70, 31.41, 29.26, 29.10, 29.04, 25.70, 22.52, 22.09, 14.39. ESI-MS calculated: 412.57; Found: 413.3
[M + H]+. Anal. (C24H36N4O2), C, H, N.
3.4.9. 2-(4-(4-(Hydroxymethyl)phenyl)-1H-1,2,3-triazol-1-yl)-N-(4-octylphenyl)acetamide (8g)
Compound 8g was obtained following the procedure described for 5a, starting from 7 and
(4-ethynylphenyl)methanol. Yield: 78%; mp 238–239 ◦C. 1H-NMR δ = 10.39 (s, 1H, –NH), 8.52 (s, 1H),
7.81 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 7.8 Hz, 2H), 7.12 (d, J = 8.6 Hz, 2H),
5.32 (s, 2H), 5.20 (t, 1H, –OH, J = 5.9 Hz, J = 5.9 Hz), 4.51 (d, J = 5.5 Hz, 2H) 2.51 (t, 2H, J = 7.8 Hz,
J = 6.3 Hz), 1.50 (m, 2H), 1.23 (bs, 10 H), 0.82 (t, 3H, J = 6.3 Hz, J = 7.0 Hz). 13C-NMR δ = 164.36, 146.65,
142.68, 138.26, 136.51, 129.61, 129.06, 127.40, 125.34, 123.22, 119.71, 63.11, 52.778, 34.98, 31.69, 31.39,
29.25, 29.10, 29.03, 22.51, 14.38. ESI-MS calculated: 420.55; Found: 421.2 [M + H]+. Anal. (C25H32N4O2),
C, H, N.
3.4.10. 2-(4-(3-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-N-(4-octylphenyl)acetamide (8h)
Compound 8h was obtained following the procedure described for 5a, starting from 7 and
2-ethynylphenol. Yield: 83%; mp 200–201 ◦C. 1H-NMR δ = 10.39 (s, 1H, –NH), 9.51 (s, 1H, –OH),
8.48 (s, 1H), 7.47 (d, J = 7.8 Hz, 2H), 7.27-7.21 (m, 3H), 7.13 (d, J = 8.2 Hz, 2H), 6.72 (s, 1H), 5.31 (s, 2H),
2.51 (t, 2H, J = 7.8 Hz, J = 6.3 Hz), 1.51 (m, 2H), 1.23 (bs, 10 H), 0.82 (t, 3H, J = 6.3 Hz, J = 7.0 Hz).
13C-NMR δ = 164.36, 158.22, 146.71, 138.26, 136.52, 132.38, 130.41, 129.06, 123.41, 119.72, 116.48, 115.34,
112.30, 52.75, 34.98, 31.71, 31.40, 29.26, 29.10, 29.04, 22.51, 14.39. ESI-MS calculated: 406.52; Found:
407.3 [M + H]+. Anal. (C24H30N4O2), C, H, N.
3.5. Biological Assays
3.5.1. Aorta Rings Assay
Male CD-1 mice (18 ± 2 g body weight, Charles River, Calco, Italy) were housed in a controlled
environment (21± 2 ◦C) and provided with standard rodent chow and water. All animals were allowed
to acclimate for four days prior to experiments and were subjected to a 12 h light–12 h dark schedule.
Experiments were conducted during the light phase. The experimental procedures, according to Italian
(DL 26/2014) and European (No. 63/2010/UE) regulations on the protection of animals used for
experimental and other scientific purposes, were approved by the Italian Ministry (No. 958/2015-PR,
14 September 2015). Mice were sacrificed to take the thoracic aorta. Aortas were cleaned of adherent
connective tissue and cut into rings 2 mm in length. Aortic rings were mounted on 2.5 mL organ baths
containing Krebs salt solution of the following composition (in mM): NaCl, 118.4; KCl, 4.7; MgSO4 1.2;
CaCl2, 1.3; KH2PO4, 1.2; NaHCO3 25.0; and glucose 11.7. The solution was maintained at 37 ◦C and
bubbled with 95% O2–5% CO2 (pH 7.4). Developed tension was measured using an isometric force
transducer (Basile; Italy) connected to a recorder. Rings were initially stretched until a resting tension
of 1g was reached and allowed to equilibrate for at least 30 min during which tension was adjusted,
when necessary, to 1 g and the bathing solution was periodically changed. In each experiment, aortic
rings were firstly challenged with PE (10−6 M) until the responses were reproducible. Subsequently,
after tissue washing, a cumulative concentration response curve to acetylcholine (10−8 to 3 × 10−5 M)
was performed.
3.5.2. Compounds and Cell Cultures
Fingolimod and PF-543 were purchased from Selleck Chemicals (München, Germany). A549,
H1975 and HCC827 human NSCLC cell lines were obtained from the American Type Culture
Collection (ATCC). These cell lines express both SphK1 and SphK2 (data not shown). All cell
lines were authenticated using Short Tandem Repeat (STR) DNA profiling and maintained
in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 20 mM
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4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, penicillin (100 IU/mL),
streptomycin (100 µg/mL), and 4 mM glutamine (ICN, Irvine, UK) in a humified atmosphere of 95%
air and 5% CO2 at 37 ◦C.
3.5.3. Cell Density Assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT))
Cells (104 cells/well) were grown in 24-well plates and exposed for 72 h to increasing doses
of the compounds (0.5 to 5 µM). The percentage of cell density was determined by using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The dose of each compound able
to reduce cell density by 50% was used as a marker of drug effect.
3.5.4. Sphingosine Kinase Activity Assay
The capability of the tested compounds to inhibit SphK1 and SphK2 enzyme activity was
measured by using the Sphingosine Kinase Activity Assay (K-3500, Echelon Biosciences, Salt Lake City,
UT, USA). The assay was performed as indicated by the manufacturer, by using sphingosine 100 µM
and ATP 10 µM. SphK1 (E-K068, Echelon Biosciences) and SphK2 (E-K069, Echelon Biosciences) were
added at a concentration of 500 ng/mL. PF-543 and the compounds 5h and 8f were tested at 10 µM.
3.5.5. Statistical Analysis
The results of cell density assays were analyzed by Student’s t test and expressed as means and
standard deviations (SDs) for three independent experiments performed in triplicates. The linear
regression test was used to evaluate the statistical significance of the results of the Sphingosine
Kinase activity assay (Graph-Pad version 5 (La Jolla, CA, USA). All reported P values were two-sided.
Analyses were performed with the BMDP New System statistical package version 1.0 for Microsoft
Windows (BMDP Statistical Software, Los Angeles, CA, USA).
4. Conclusions
The aim of the present study was to identify novel SphK1 and/or SphK2 inhibitors useful
in further exploring the use of these pharmacological targets in the anticancer research field. According
to the finding that a key characteristic feature for most of the already reported inhibitors is a highly
lipophilic backbone connected by a linker to a polar (mainly basic) head group, we started this project
with the synthesis of two series of compounds (2a–2g and 3a–3g) where a pyrrolidine spacer was used
to link several lipophilic tails to a two- or three-unit polar head. Only the 4-octylphenyl derivatives
2d and 3d showed an inhibitory activity in the aorta rings based assay and for this reason this scaffold
was selected for further development of this project. Two series of 1,4-disubstituted 1,2,3-triazoles
(5a–5h and 8a–8h) were synthesized and evaluated for their ability to interfere with the Ach induced
relaxation of aortic rings. Then, their capability in inhibiting proliferation of several cell lines expressing
both SphK1 and SphK2 was investigated. Compounds 5h and 8f were the most interesting in terms
of antiproliferative activity, and their selectivity towards the two isoforms was tested. Compound
8f produced a more pronounced inhibition of SphK1 than SphK2, while 5h inhibited both the enzyme
isoforms. Co-crystal structures of SphK1 with three inhibitors have been obtained [17,23,24]. All the
crystallized inhibitors occupy the J-shaped channel where the alkyl chain of S1P resides. Key residues
in the binding site are largely conserved between SphK1 and SphK2 [25]. The molecular model
of 5h shows that it can adapt to both isoforms because of its simpler and shorter structure. Compound
8f is not only able to accommodate the 4-octylphenyl moiety in the J channel, but it presents a higher
complementarity with the active site of SphK1 due to its flexible and polar head; that makes this
compound a novel selective inhibitor of SphK1.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/11/2332/s1.
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